Madrid, Spain.Langley RG, Gooderham M, Papp KA, et al. Efficacy and safety of long-term tildrakizumab for plaque psoriasis: 4-year results from reSURFACE 2. Poster presented at: 28th European Academy of Dermatology and Venereology Congress
Advertisement
Articles by Madrid, Spain.Langley RG, Gooderham M, Papp KA, et al. Efficacy and safety of long-term tildrakizumab for plaque psoriasis: 4-year results from reSURFACE 2. Poster presented at: 28th European Academy of Dermatology and Venereology Congress
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
Newly Unveiled ACA Premiums Show 26% Average Increase Before Subsidy Expiration
2
FDA Guidance to Remove One of the Largest Barriers to Biosimilar Development
3
Biktarvy Improves ART Persistence for People With HIV and Mental Health Disorders
4
Cancer Care in Transition: Navigating Breakthrough Therapies Amid Economic Strain
5
